Advisor

George Q. Mills, M.D. - FDA Consultant

Dr Mills serves as our consultant liaison between the FDA and NuView. Dr. Mills formerly served as Division Director of Medical Imaging and Hematology Products in the Office of Oncology Drug Products, part of the U.S. Food and Drug Administration's (FDA) Center for Drug Evaluation and Research (CDER). In his recent position as Division Director at the FDA, Dr. Mills was responsible for the review and approval of diagnostic and radio labeled therapeutic drugs and biologics. He managed a staff involved in the review of the Radioactive Drug Research Committee (RDRC) program, therapeutic and imaging Investigational New Drug Applications (INDs), Biologic License Applications (BLAs) and New Drug Applications (NDAs). Dr. Mills was also actively involved with the FDA's Critical Path Initiative since its inception in 2004. Previously, Dr. Mills held several senior roles at the FDA, including Branch Chief and designated Acting Deputy Division Director of the Biologics Oncology Division at the Center for Biologics Evaluation and Research (CBER) and CDER. In these roles, he served as Medical Chief, providing expertise in medical diagnostic imaging and therapeutic radiopharmaceutical oncologic biologics and drugs. He also served as the CBER/CDER expert in conjunction with the review of radiographic imaging submissions in support of licensure submissions.